Can IASO Bio and Instituto Butantan make CAR-T therapy affordable for Brazil’s public health system?
IASO Bio and Instituto Butantan are betting on local CAR-T development in Brazil. Find out what this could change for access, cost, and cancer care.
How Brazil’s GMP approval for pembrolizumab biosimilar changes global biosimilar dynamics
Blau Farmacêutica’s pembrolizumab biosimilar earns ANVISA GMP approval—see what this means for Brazil’s global position in cancer immunotherapy.
Brazil rollout puts Bavarian Nordic’s chikungunya vaccine under regulatory and execution scrutiny
Find out how Bavarian Nordic’s Brazil rollout with Eurofarma puts its chikungunya vaccine to the ultimate regulatory and execution test.
Can early access programs reshape the approval arc for rare disease gene therapies?
GenSight Biologics S.A.’s early access rollout of GS010/LUMEVOQ in France and Israel has drawn new attention to how regulators are quietly repurposing compassionate use frameworks into strategic regulatory sandboxes for advanced therapies. As rare disease gene therapies edge closer to commercial viability, a patchwork of early access programs across key jurisdictions is beginning to influence […]